Without covid the company would be screwed
Post# of 154115
(Total Views: 775)
Posted On: 09/30/2020 5:49:08 PM
Without covid the company would be screwed
I write this objectively and giving Nader massive credit for rescuing leronlimab off the trash heap, but every time I hear him patting himself on the back I think about how bad it would be without covid....
The warrant exercises from the Vyera deal share price bump would have diminished quickly so that funding source would have dried up.
There would have still been Samsung payments due and there would not have been money for the cancer and NASH trials.
As Nader said in the last CC, the restrictive terms of the Vyera deal would have made it very difficult to get a licensing deal with another company on other indications.
The BLA would still have been given an RTF and delayed indefinitely, so no revenue in sight.
We would have been up the proverbial financial creek without a paddle.
I can't give his incessant hyping of leronlimab credit for the increase in share price due to covid because other therapeutic stocks have rocketed up with relatively small amounts of PR pumping. HGEN went from 35 cents to well over 6 bucks (before the reverse split) and they have almost no public presence. If anything, running the mild to moderate trial was a waste of money (it could still turn out positive but right now it seems superfluous).
So we'll see how it goes from here but I just roll my eyes when Nader starts reciting his litany of accomplishments because the truth is that his seat would be incredibly hot right now if covid had not appeared.
I write this objectively and giving Nader massive credit for rescuing leronlimab off the trash heap, but every time I hear him patting himself on the back I think about how bad it would be without covid....
The warrant exercises from the Vyera deal share price bump would have diminished quickly so that funding source would have dried up.
There would have still been Samsung payments due and there would not have been money for the cancer and NASH trials.
As Nader said in the last CC, the restrictive terms of the Vyera deal would have made it very difficult to get a licensing deal with another company on other indications.
The BLA would still have been given an RTF and delayed indefinitely, so no revenue in sight.
We would have been up the proverbial financial creek without a paddle.
I can't give his incessant hyping of leronlimab credit for the increase in share price due to covid because other therapeutic stocks have rocketed up with relatively small amounts of PR pumping. HGEN went from 35 cents to well over 6 bucks (before the reverse split) and they have almost no public presence. If anything, running the mild to moderate trial was a waste of money (it could still turn out positive but right now it seems superfluous).
So we'll see how it goes from here but I just roll my eyes when Nader starts reciting his litany of accomplishments because the truth is that his seat would be incredibly hot right now if covid had not appeared.
(9)
(0)